Axsome Therapeutics
AXSM
184 hedge funds and large institutions have $1.31B invested in Axsome Therapeutics in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 64 increasing their positions, 52 reducing their positions, and 29 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 52
21% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 29
3% more funds holding
Funds holding: 179 → 184 (+5)
2.6% less ownership
Funds ownership: 64.22% → 61.62% (-2.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
33% less capital invested
Capital invested by funds: $1.95B → $1.31B (-$643M)
74% less call options, than puts
Call options by funds: $14.1M | Put options by funds: $53.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$24.4M |
| 2 |
Two Sigma Investments
New York
|
+$10.3M |
| 3 |
Morgan Stanley
New York
|
+$6.58M |
| 4 |
Millennium Management
New York
|
+$6.13M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22.1M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$18.8M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$16.9M |
| 5 |
Janus Henderson Group
London,
|
-$16.7M |
AXSM Hedge Fund Activity: Q1 2021 in Review
184 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2021, worth a combined $1.31B — down 33% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new AXSM positions and 29 closed out — a net gain of 6 holders — while 64 added to existing stakes and 52 trimmed.
The largest buyer was Iridian Asset Management, adding an estimated $24.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $29M.
- 184 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2021, up from 179 in Q4 2020.
- Funds reported $1.31B of Axsome Therapeutics stock for Q1 2021, down 33% quarter-over-quarter.
- 35 funds opened new Axsome Therapeutics positions in Q1 2021 and 29 closed out, a net change of +6 holders.
- The largest Axsome Therapeutics buyer in Q1 2021 was Iridian Asset Management, an estimated $24.4M added.
- The largest Axsome Therapeutics seller in Q1 2021 was T. Rowe Price Associates, an estimated $29M sold.
Based on aggregated 13F filings for Q1 2021.